Tagged with M

Commercial Eyes What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting a medicine registered; getting a product reimbursed via the Pharmaceutical Benefits Scheme (PBS); dealing with the challenges of PBS reforms;…

Galderma As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player in the worldwide dermatology market formed in 1981 as a L’Oreal-Nestle joint venture. Its aspirations are reflected in its commitment…

Amgen Australia What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive advantages and tend to be on their own in a certain clinical space and treatment paradigm. Amgen sells very few…

Pharmaceutical Industry Council (PIC) 2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC). Would you please introduce the organization, and tell us about the main milestones and achievements since you began your tenure…

Novotech (Australia) Pty Limited One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our particular business, there is very minimal effect. Because Novotech is a service company, most of its clients are engaged in…

UTI Pharma South Africa We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head of a much bigger company. To what extent has the distributor now taken a new dimension in terms of financials,…

Government of Australia The Ministry for Innovation, Industry, Science and Research was created in December 2007 with the election of the Labor government. To begin, would you please give a brief introduction to the ministry and highlight its most significant achievements and milestones in this relatively short period of time? The whole point…

Nycomed Latin America The executive management of Nycomed said in an interview that ‘the tremendous growth of the pharmaceutical industry will not occur in either Europe or the United States, but in emerging economies such as Latin America.’ What is the relative importance of Nycomed Latin America for the company from a global…

Denver Farma Could you give us an overview of the generics sector in Argentina as it stands at the moment? The generics market in Argentina was started immediately after the regulation regarding generic prescription was introduced in 2002. However, this law didn’t include approval for products of generic denomination. Because of this,…

Datapharm Australia Pty Ltd The Australian pharmaceutical sector has seen recent innovations through PBS reform and various working groups shaping the future of the industry. Can you comment on how Datapharm is reacting to these opportunities? Datapharm has actually put in a submission to the review of the National Innovation System, highlighting that innovation…

Genzyme Australia What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of the company’s products, given they are targeted therapies, are not reimbursed through the PBS, but through other government funding mechanisms.…

Medicines Australia To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the national industry association for innovative pharmaceutical companies. . Just about every company engaged in the research and discovery of new medicines in Australia is a member of the association, so we have the capacity…